Connection

Yee-Sin Leo to Antibodies, Viral

Back to Details
This is a "connection" page, showing publications Yee-Sin Leo has written about Antibodies, Viral.
Yee-Sin Leo
Connection Strength
0.249
Antibodies, Viral
  1. SARS in Singapore--predictors of disease severity. Ann Acad Med Singap. 2006 May; 35(5):326-31.
    View in: PubMed
    Score: 0.032
  2. Clinical and laboratory findings of SARS in Singapore. Ann Acad Med Singap. 2006 May; 35(5):332-9.
    View in: PubMed
    Score: 0.032
  3. Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. N Engl J Med. 2021 10 07; 385(15):1401-1406.
    View in: PubMed
    Score: 0.023
  4. Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19. Cell Rep Med. 2021 02 16; 2(2):100193.
    View in: PubMed
    Score: 0.022
  5. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerg Microbes Infect. 2020 Dec; 9(1):900-902.
    View in: PubMed
    Score: 0.022
  6. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat Commun. 2020 06 01; 11(1):2806.
    View in: PubMed
    Score: 0.021
  7. Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity. Sci Rep. 2018 01 30; 8(1):1860.
    View in: PubMed
    Score: 0.018
  8. Viral and Antibody Kinetics, and Mosquito Infectivity of an Imported Case of Zika Fever Due to Asian Genotype (American Strain) in Singapore. Viruses. 2018 01 18; 10(1).
    View in: PubMed
    Score: 0.018
  9. Serodiagnosis of dengue virus infection using commercially available antibody and NS1 antigen ELISAs. Diagn Microbiol Infect Dis. 2017 Jun; 88(2):120-124.
    View in: PubMed
    Score: 0.017
  10. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis. 2012 Apr 01; 205(7):1147-54.
    View in: PubMed
    Score: 0.012
  11. Virus-specific RNA and antibody from convalescent-phase SARS patients discharged from hospital. Emerg Infect Dis. 2004 Oct; 10(10):1745-50.
    View in: PubMed
    Score: 0.007
  12. Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. Clin Infect Dis. 2021 11 02; 73(9):e2932-e2942.
    View in: PubMed
    Score: 0.006
  13. Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir. Front Immunol. 2021; 12:680188.
    View in: PubMed
    Score: 0.006
  14. Diagnostic performance of COVID-19 serological assays during early infection: A systematic review and meta-analysis of 11 516 samples. Influenza Other Respir Viruses. 2021 07; 15(4):529-538.
    View in: PubMed
    Score: 0.006
  15. Epidemiology and Relative Severity of Influenza Subtypes in Singapore in the Post-Pandemic Period from 2009 to 2010. Clin Infect Dis. 2017 Nov 13; 65(11):1905-1913.
    View in: PubMed
    Score: 0.004
  16. The immune response to 6-monthly versus annual standard dose inactivated trivalent influenza vaccination in older people: study protocol for a randomised clinical trial. Trials. 2017 02 10; 18(1):67.
    View in: PubMed
    Score: 0.004
  17. Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clin Diagn Lab Immunol. 2004 Mar; 11(2):362-71.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.